Ensysce Biosciences, Inc. (NASDAQ:ENSC) Sees Large Increase in Short Interest

Ensysce Biosciences, Inc. (NASDAQ:ENSCGet Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 246,300 shares, an increase of 9.1% from the December 31st total of 225,700 shares. Currently, 8.8% of the company’s stock are short sold. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is presently 0.2 days.

Ensysce Biosciences Price Performance

ENSC opened at $1.62 on Thursday. Ensysce Biosciences has a 12 month low of $0.77 and a 12 month high of $9.84. The stock has a fifty day moving average price of $1.14 and a 200-day moving average price of $1.41.

Ensysce Biosciences (NASDAQ:ENSCGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.19. The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $0.59 million. Ensysce Biosciences had a negative return on equity of 6,580.48% and a negative net margin of 401.40%. Analysts expect that Ensysce Biosciences will post -4.55 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ensysce Biosciences stock. Anson Funds Management LP bought a new position in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSCFree Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 36,261 shares of the company’s stock, valued at approximately $65,000. Anson Funds Management LP owned about 2.83% of Ensysce Biosciences at the end of the most recent reporting period. Institutional investors own 30.97% of the company’s stock.

Ensysce Biosciences Company Profile

(Get Free Report)

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology.

Featured Stories

Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.